Liquid Biopsy Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 7.2 billion
Estimated Base Value
2035 Forecast
US$ 37.0 billion
Projected Market Value
CAGR 2026–2035
17.8%
Compound Annual Growth
Largest Segment
Assay Kits & Reagents
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Guardant Health
Emerging Players
Tempus, C2i Genomics
Liquid Biopsy Market Overview
The Liquid Biopsy Market focuses on non-invasive diagnostic technologies and services that analyze biomarkers in bodily fluids, primarily blood, for disease detection, monitoring, and characterization. This market includes the development and commercialization of instruments, reagents, kits, and software solutions designed to isolate and analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), exosomes, and other relevant biomolecules. Its primary applications are in early cancer detection, recurrence monitoring, personalized treatment selection, and therapy response assessment, serving hospitals, clinics, reference laboratories, and pharmaceutical companies.
The Liquid Biopsy Market is estimated at $7.2 Bn in 2025 and is forecast to reach $37.0 Bn in 2035, growing at a CAGR of 17.8% from 2025 to 2035. Demand is driven by the increasing global incidence of various cancer types and the need for minimally invasive diagnostic and monitoring tools. However, the high cost of liquid biopsy tests and challenges in standardization and sensitivity for early-stage cancers present limitations to market expansion.
The market is segmented by Type (Assay Kits & Reagents, Instruments & Platforms, Services, Software & Data Analysis Solutions), Technology (Next-Generation Sequencing, Polymerase Chain Reaction Based, Droplet Digital PCR), Application (Oncology, Non-Invasive Prenatal Testing, Infectious Disease Diagnosis), Source (Blood Plasma & Serum, Urine, Cerebrospinal Fluid), End-User (Hospitals & Clinics, Reference Laboratories, Academic & Research Institutions), and Biomarker Type (Circulating Tumor DNA, Circulating Tumor Cells, Exosomes & Extracellular Vesicles). Key companies include Guardant Health, Exact Sciences, Natera, Freenome, and Caris Life Sciences. The full report covers these segments across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Market Definition & Overview
The Liquid Biopsy Market comprises the global commercial sector dedicated to non-invasive diagnostic technologies and services that analyze biomarkers present in bodily fluids, primarily blood, for disease detection, monitoring, and characterization. This market encompasses the development, manufacturing, and commercialization of instruments, reagents, kits, and software solutions used to isolate and analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), exosomes, and other relevant biomolecules. Its primary applications include early cancer detection, recurrence monitoring, personalized treatment selection, and therapy response assessment, driving a paradigm shift towards less invasive and more dynamic patient management in oncology and other disease areas.
Scope
- Global geographic market coverage.
- Focus on clinical diagnostic and monitoring applications.
- Market analysis covering the period from 2025 to 2035.
- Segmentation by biomarker type, technology platform, and disease application.
Inclusions
- Circulating tumor DNA (ctDNA) analysis kits and services.
- Circulating tumor cell (CTC) isolation and enumeration platforms.
- Exosome isolation and analysis technologies for diagnostic purposes.
- Next-generation sequencing (NGS) and PCR-based liquid biopsy assays.
- Bioinformatics and data analysis solutions for liquid biopsy results.
- Companion diagnostic tests utilizing liquid biopsy methods.
Exclusions
- Traditional invasive tissue biopsy procedures and associated equipment.
- General laboratory consumables not specific to liquid biopsy.
- Research-use-only (RUO) liquid biopsy products without clinical applications.
- Medical imaging techniques such as MRI, CT, or PET scans.
- Pharmaceutical drugs for cancer treatment.
Market Size Forecast
Executive Summary
• The Liquid Biopsy market is valued at $7.2 Bn in 2025 and is forecast to reach $37.0 Bn by 2035, reflecting a robust CAGR of 17.8% as demand accelerates across every major segment and region over the ten-year outlook.
• Assay Kits & Reagents leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Strategic M&A is rapidly consolidating the liquid biopsy market, driven by a race for advanced IP and integrated diagnostic platforms, fundamentally altering competitive dynamics and market leadership across key therapeutic areas.
• Expanding clinical utility across early detection, recurrence monitoring, and companion diagnostics serves as the paramount growth catalyst, propelling significant market adoption across diverse oncology segments and global regions.
• Advancements in NGS and AI-driven bioinformatics are significantly enhancing assay sensitivity and specificity, while evolving global regulatory clarity increasingly dictates market entry and product commercialization strategies for novel liquid biopsy platforms.
• Regional disparities in reimbursement policies and healthcare infrastructure critically influence liquid biopsy adoption rates, necessitating localized strategic approaches for market penetration and segment-specific product development across diverse global economies.
• Sustained investment in R&D is heavily concentrated on automation and standardization, critically addressing supply chain vulnerabilities and facilitating the scalable deployment of liquid biopsy platforms for broader clinical integration.
• Future differentiation hinges on robust clinical evidence, comprehensive multi-cancer screening capabilities, and seamless integration into diagnostic workflows, requiring providers to offer integrated solutions beyond standalone technological superiority.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Liquid Biopsy Market was valued at $7.2 billion in the base year.
Future Market Expansion
The market is projected to reach $37.0 billion by the forecast year.
Robust Growth Outlook
This significant expansion is driven by a compound annual growth rate (CAGR) of 17.8% over the forecast period.
Oncology Dominance
Oncology applications are expected to remain the leading segment, fueled by the increasing prevalence of cancer and demand for non-invasive diagnostic tools.
North American Leadership
North America is anticipated to hold a leading market share, attributed to advanced healthcare infrastructure and robust R&D activities in the region.
Technological Advancements
A key trend is the continuous technological evolution in sequencing and analytical platforms, enhancing the accuracy and scope of liquid biopsy assays.
Market Dynamics
Market Trends
- Increased adoption of non-invasive cancer detection methods is observed.
- Technological advancements in sequencing and assay development are prominent.
- Shift towards early disease detection and personalized medicine is evident.
- Growing integration of AI and machine learning for data analysis prevails.
Growth Drivers
- Rising global incidence of various cancer types fuels demand.
- Demand for minimally invasive diagnostic and monitoring tools is high.
- Increasing awareness and acceptance of liquid biopsies drives growth.
- Supportive government initiatives and funding for cancer research boost the market.
Restraints
- High cost of liquid biopsy tests limits widespread adoption.
- Lack of standardization impedes data comparability and clinical utility.
- Limited sensitivity for early-stage cancers remains a significant hurdle.
- Complex regulatory and reimbursement pathways delay market entry.
Opportunities
- Expansion into new applications like infectious diseases offers growth.
- Developing highly sensitive multi-cancer early detection tests is a key opportunity.
- Geographical market expansion, especially in emerging economies, is promising.
- Strategic collaborations and partnerships among industry players create avenues.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Assay Kits & ReagentsInstruments & PlatformsServicesSoftware & Data Analysis Solutions |
| By Technology | Next-Generation SequencingPolymerase Chain Reaction BasedDroplet Digital PCRFluorescence in Situ HybridizationMicroarray TechnologyImmunocapture & ImmunostainingOther Technologies |
| By Application | OncologyNon-Invasive Prenatal TestingInfectious Disease DiagnosisTransplant Rejection MonitoringReproductive HealthPharmacogenomicsOther Applications |
| By Source | Blood Plasma & SerumUrineCerebrospinal FluidSalivaOther Body Fluids |
| By End-User | Hospitals & ClinicsReference LaboratoriesAcademic & Research InstitutionsPharmaceutical & Biotechnology CompaniesContract Research OrganizationsDiagnostic Centers |
| By Biomarker Type | Circulating Tumor DNACirculating Tumor CellsExosomes & Extracellular VesiclesCell-Free RNAProteinsOther Biomarkers |
Regional Analysis
- North America leads the liquid biopsy market due to robust healthcare infrastructure, significant R&D investments, and a high prevalence of cancer. Early adoption of advanced diagnostic technologies and supportive reimbursement policies further cement its dominant position in the global market.
- Asia-Pacific is the fastest-growing region, driven by its large and aging population, increasing cancer incidence, and improving healthcare access. Rising disposable incomes, growing awareness about early diagnosis, and government initiatives promoting medical innovation contribute significantly to its rapid market expansion.
- Europe exhibits a notable trend of increasing integration of liquid biopsy into routine clinical practice, particularly for cancer monitoring and treatment selection. Growing collaborative research efforts and a strong emphasis on personalized medicine are accelerating its adoption across various European countries.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- North America leads the liquid biopsy market due to significant R&D investment, robust healthcare infrastructure, and early adoption of advanced diagnostic technologies.
- Favorable reimbursement policies and high clinical trial activity further drive market expansion.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Latin America is an emerging market with significant potential due to increasing healthcare awareness and improving economic conditions in key countries.
- Adoption is primarily concentrated in private healthcare sectors and major urban centers.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Europe is a mature market with strong research capabilities and a growing geriatric population, fueling demand for non-invasive cancer diagnostics.
- Evolving regulatory frameworks are supporting broader adoption, particularly for established applications.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Asia Pacific is experiencing rapid growth driven by increasing cancer incidence, rising healthcare expenditures, and improving access to advanced medical technologies.
- Government initiatives and a large patient pool make it a key future growth engine.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region is a nascent but rapidly expanding market, especially in GCC countries, propelled by government investments in healthcare infrastructure and a rising prevalence of chronic diseases.
- Challenges remain in wider accessibility and affordability.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads the global liquid biopsy market due to extensive R&D, high adoption rates of advanced diagnostics in oncology, and a robust reimbursement landscape supporting innovative technologies. Its large patient pool and presence of major diagnostic companies drive continuous innovation and market expansion. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil is a key growth market in South America, fueled by its large population, increasing cancer burden, and expanding private healthcare sector. Growing awareness and investment in precision oncology are accelerating the adoption of liquid biopsy for non-invasive cancer detection and monitoring. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany holds a significant share in Europe, propelled by its advanced healthcare infrastructure, strong research ecosystem, and high adoption of innovative diagnostic technologies. Leading oncology centers and a robust diagnostics industry are key drivers for liquid biopsy market growth. |
| 4 | China | US$ XX.X Mn | XX.X% | China is a rapidly expanding liquid biopsy market due to its immense cancer patient population, significant government investment in healthcare and biotech, and swift adoption of advanced diagnostic technologies. Domestic companies are rapidly innovating and expanding market access. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is rapidly investing in healthcare infrastructure modernization and advanced diagnostic technologies, including liquid biopsy, as part of its Vision 2030. Increasing cancer incidence and high per capita healthcare spending are key market drivers. |
Countries Covered (25)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Guardant Health | XX.X% | To extend its leadership in advanced cancer care by providing comprehensive liquid biopsy solutions for therapy selection, recurrence monitoring, and early detection across the cancer care continuum. | — | — | Guardant360Guardant RevealGuardant SHIELD+1 |
| 2 | Exact Sciences | XX.X% | To become a leading global cancer diagnostics company by developing and commercializing highly accurate and accessible tests across the cancer care continuum, from screening to treatment selection. | — | — | CologuardOncotype DXOncotype MAP+1 |
| 3 | Natera | XX.X% | To leverage its proprietary cfDNA technology and statistical algorithms to offer best-in-class genetic testing solutions across reproductive health, oncology, and organ transplant. | — | — | PanoramaProsperaSignatera+1 |
| 4 | Freenome | XX.X% | To develop a multi-omics platform for early cancer detection and precision oncology by integrating cell-free DNA, RNA, and protein biomarkers. | — | — | Multi-omics platformColorectal cancer screening testBiomarker discovery services |
| 5 | Caris Life Sciences | XX.X% | To provide comprehensive molecular profiling and real-world data analytics to guide precision oncology treatment decisions and accelerate drug development. | — | — | Caris Molecular IntelligenceCaris CODECaris Precision Oncology Alliance+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Guardant Health, Exact Sciences, Natera, Freenome, Caris Life Sciences, Burning Rock Biotech, NeoGenomics, Personalis, Angle plc, MDxHealth, Menarini Silicon Biosystems, Epic Sciences, Lucence Health, Biodesix, CellMax Life, VolitionRx, Chronix Biomedical, Exai Bio, AnPac Bio-Medical Science, Biological Dynamics
The global Liquid Biopsy market features a competitive landscape led by Guardant Health, Exact Sciences, Natera, Freenome, Caris Life Sciences, and Burning Rock Biotech, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Guardant Health
Exact Sciences
Natera
Freenome
Caris Life Sciences
Burning Rock Biotech
NeoGenomics
Personalis
Angle plc
MDxHealth
Menarini Silicon Biosystems
Epic Sciences
Lucence Health
Biodesix
CellMax Life
VolitionRx
Chronix Biomedical
Exai Bio
AnPac Bio-Medical Science
Biological Dynamics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Innovate Diagnostics Launches Next-Gen Multi-Cancer Early Detection Test
Innovate Diagnostics announced the commercial launch of 'CancerDetect Pro,' a highly sensitive multi-cancer early detection (MCED) liquid biopsy test. This new test aims to revolutionize cancer screening by identifying over 50 cancer types from a single blood draw using advanced genomic sequencing.
Roche Diagnostics & BioGenomics Partner for Precision Oncology Companion Diagnostics
Roche Diagnostics and BioGenomics Inc. have formed a strategic partnership to develop and commercialize novel liquid biopsy companion diagnostics. This collaboration seeks to accelerate the identification of patients for targeted therapies across various oncology indications, significantly advancing precision medicine.
Liquid Biopsy Innovator CureSense Secures US$ XX.X Series C Funding
CureSense Inc., a leading developer in non-invasive cancer recurrence monitoring through liquid biopsies, successfully closed a US$ XX.X Series C funding round. The substantial capital infusion will fuel expansion of clinical trials, accelerate product development, and support commercialization efforts for its advanced platforms.
Guardant Health's Blood-Based CRC Screening Test Shows Robust Pivotal Trial Results
Guardant Health announced compelling positive results from its pivotal clinical trial for a blood-based colorectal cancer (CRC) screening test, demonstrating high sensitivity and specificity. These findings are crucial for securing regulatory approvals and expanding the test's integration into routine screening guidelines, potentially broadening market access.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $7.2 Bn |
| Market Size (Forecast) | $37.0 Bn |
| CAGR | 17.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 25 Countries |
| Segments Covered | 6 Segments, 35 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Liquid Biopsy Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Liquid Biopsy Market is estimated at $7.2 Bn in 2025. It is forecast to reach $37.0 Bn in 2035, indicating substantial growth over the forecast period.
The Liquid Biopsy Market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 17.8% from 2025 to 2035. This growth is driven by increasing demand for non-invasive diagnostic tools.
The main segments include Type (Assay Kits & Reagents, Instruments), Technology (Next-Generation Sequencing, PCR Based), Application (Oncology, NIPT), Source (Blood Plasma & Serum, Urine), End-User (Hospitals & Clinics, Reference Laboratories), and Biomarker Type (Circulating Tumor DNA, Circulating Tumor Cells).
Leading companies in the Liquid Biopsy Market include Guardant Health, Exact Sciences, Natera, Freenome, Caris Life Sciences, Burning Rock Biotech, NeoGenomics, Personalis, Angle plc, MDxHealth, Menarini Silicon Biosystems, and Epic Sciences.
The Liquid Biopsy market report covers market size and growth forecasts, detailed segmentation by Type, Technology, Application, Source, End-User, and Biomarker Type, and regional analysis across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. It also profiles key industry players.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Liquid Biopsy Technologies Market
$4.0 Bn in 2025 · 16.9% CAGR
Biopsy Guidance Systems Market
$1.6 Bn in 2025 · 6.5% CAGR
Advanced Molecular Diagnostics Market
$14.6 Bn in 2025 · 16.2% CAGR
AI Diagnostics Market
$2.1 Bn in 2025 · 16.3% CAGR
AI Echocardiography Market
$300.0 Mn in 2025 · 20.3% CAGR
AI Genomic Diagnostics Market
$800.1 Mn in 2025 · 24.0% CAGR
AI Histology Market
$386.1 Mn in 2025 · 20.5% CAGR
AI in Radiology Market
$1.2 Bn in 2025 · 18.4% CAGR